STRENGTHS AND LIMITATIONS OF THIS STUDY
The multicentre randomised controlled design minimises systematic bias.
This study includes a prospective, trial-based economic evaluation.
The adaptive treatment strategy evaluated is clinically attractive.
Endoscopy is not mandatory in the study, although it remains the gold standard for confirmation of a disease relapse.
Blinding is not possible due to the absence of a sham intervention.
Crohn’s disease (CD) and ulcerative colitis (UC) are the two main entities of inflammatory bowel disease (IBD). IBD is a chronic inflammatory disorder of the gastrointestinal tract that is characterised by relapsing and remitting episodes. Vedolizumab (VDZ) is an approved and extensively used effective maintenance treatment for IBD, with a gut-selective mode of action.
This post was originally published on https://bmjopen.bmj.com